Detailed Narrative
Strong Q1 FY27 Financial Performance
Indo Borax & Chemicals Limited reported a robust Q1 FY27, with operating revenue growing 31.34% year-on-year to ₹70.36 crores, up from ₹53.57 crores in Q1 FY26. This growth was attributed to strong execution, improved capacity utilization, and better product realizations. EBITDA increased significantly by 62.16% to ₹19.8 crores, resulting in an EBITDA margin of 28.1%, while net profit surged by 59.31% to ₹16.25 crores, achieving a PAT margin of 22.3% and an EPS of ₹5.07.
Strategic Acquisition of Kronox Lab Sciences
A key highlight of the quarter was the Board's approval in August 2026 for the acquisition of a 64.26% equity share in Kronox Lab Sciences, a listed specialty chemical player. This strategic move aims to diversify Indo Borax's product portfolio into niche, high-end specialty chemicals, leveraging Kronox's 185 products, global presence, and strong distribution network. Management expects significant value synergies by combining Kronox's market reach with Indo Borax's operational efficiencies and supply chain expertise.
Funding Strategy for Kronox Acquisition
The acquisition of Kronox Lab Sciences, valued at approximately ₹250 crores for the 64.26% stake, is being financed through a multi-pronged approach. This includes ₹134-135 crores from Indo Borax's internal accruals and sale of non-core assets, an additional ₹48-50 crores from the sale of commercial office spaces, and a term loan to cover the ₹151 crore open offer amount and the remaining payment to promoters. A contingency of ₹25 crores has also been committed by the promoter group, ensuring total funding of ₹432 crores against a required ₹400 crores.
Planned Capex for Growth and Diversification
Indo Borax has outlined a ₹50 crore Capex plan over the next 2-3 years, primarily allocated to Boron Oxide (₹20 crores) and Boric Acid (₹20-25 crores) capacities, with some investment in Zinc Borate. Separately, Kronox Lab Sciences has a ₹110 crore Capex plan, with ₹80 crores already available in cash. The first phase of Kronox's Capex (₹55-60 crores) is fully funded by internal accruals, with the entire project expected to take 18-24 months and yield full revenue impact by FY30-31.
Market Leadership and Product Strategy
Indo Borax maintains a strong position in the Indian Boric Acid market, commanding almost 50% market share, particularly in the steel and ceramic industries. The company is actively expanding its production of Disodium Octaborate Tetrahydrate (DOT), targeting 1,500 tons this year, up from 900 tons last year, utilizing its 6,000-ton capacity. Additionally, there's a strategic focus on increasing the base in higher-margin IP-grade Boric Acid for the pharma and personal care sectors, aiming for further product mix improvement.
FY27 Outlook and Margin Expectations
For the full fiscal year 2027, Indo Borax projects revenues of ₹250-260 crores, an increase from ₹215 crores in FY26, with an EBITDA margin target of 20%. This implies an 11-12% growth in absolute EBITDA. However, management cautioned that Q2 is typically a low-volume monsoon quarter, and the persistence of high raw material costs due to geopolitical events means Q1's 28.1% EBITDA margin may not be sustainable for the full year.
Integration and Leadership Transition
Post-acquisition, the leadership strategy for Kronox involves a combination of continuity and new oversight. Kronox's three promoters will continue for a considerable period under contract and retain a 9.95% equity stake. Indo Borax's senior leadership, including the CFO, Chief Commercial Officer, Executive Director, and heads of Manufacturing and Supply Chain, will provide strategic direction to both companies, ensuring a smooth transition and focusing on operational synergies. The entities will continue to operate as separate listed companies for the foreseeable future.